Bruker Corp

Chart & Performance

D1W1MN

P/E

21.74

P/S

3.13

EPS

2.82

Div Yield, %

0.32%

Shrs. gr., 5y

-1.31%

Rev. gr., 5y

9.36%

Revenues

2.96b

+17.14%

Net income

427m

+44.03%

CFO

350m

+33.63%

Dividend

Aug 30, 20240.05 USD/sh

Earnings

Apr 30, 2025

Profile

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

URL

https://www.bruker.com/

IPO date

Aug 04, 2000

Employees

8,525

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	2,964,500 17.14%	2,530,700 4.67%
Cost of revenue	2,475,400	2,068,300
Unusual Expense (Income)
NOPBT	489,100	462,400
NOPBT Margin	16.50%	18.27%
Operating Taxes	117,700	116,400
Tax Rate	24.06%	25.17%
NOPAT	371,400	346,000
Net income	427,200 44.03%	296,600 7.04%
Dividends	(29,400)	(29,800)
Dividend yield	0.27%	0.29%
Proceeds from repurchase of equity	(142,800)	(260,300)
BB yield	1.32%	2.55%
Debt
Debt current	144,500	18,700
Long-term debt	1,317,400	1,251,700
Deferred revenue	91,500	56,200
Other long-term liabilities	256,000	253,900
Net debt	965,300	601,900
Cash flow
Cash from operating activities	350,100	262,000
CAPEX	(106,900)	(119,000)
Cash from investing activities	(326,000)	(239,300)
Cash from financing activities	(193,400)	(415,200)
FCF	(6,100)	158,700
Balance
Cash	488,300	645,500
Long term investments	8,300	23,000
Excess cash	348,375	541,965
Stockholders' equity	2,367,600	1,948,600
Invested Capital	2,776,225	2,015,135
ROIC	15.50%	18.13%
ROCE	15.32%	17.65%
EV
Common stock shares outstanding	147,200	149,400
Price	73.48 7.51%	68.35 -18.54%
Market cap	10,816,256 5.92%	10,211,490 -20.41%
EV	11,817,656	10,819,490
EBITDA	604,000	550,400
EV/EBITDA	19.57	19.66
Interest	16,400	16,100
Interest/NOPBT	3.35%	3.48%